Browse the evidence

Co-ingesting cluster dextrin (CDX) with protein after resistance exercise does not increase myofibrillar protein synthesis or total amino acid availability compared to glucose, despite enhancing intramuscular mTORC1 signaling.

If you are eating protein after resistance training, switching from glucose to cluster dextrin will not help you build more muscle. While CDX might trigger slightly higher signaling markers (mTORC1), it does not translate to actual muscle protein synthesis gains compared to regular glucose. Stick to what works and costs less.

Genetic deletion or specific knockdown of the mitochondrial protein MCJ (DnaJC15) in brown adipose tissue promotes thermogenesis and protects against diet-induced obesity through a UCP1-independent mechanism mediated by eIF2α signaling.

This research suggests that targeting the MCJ protein in fat cells could help the body burn more energy and resist weight gain, even without relying on the classic 'uncoupling' protein UCP1. While this is currently a genetic finding in mice, it points to potential future therapies for obesity that enhance metabolic rate through mitochondrial stress responses.

Resmetirom, a thyroid hormone receptor beta (THRβ) agonist, is the first FDA-approved drug specifically for MASH, demonstrating significant improvement in both steatohepatitis and fibrosis in patients with advanced liver fibrosis.

Resmetirom is the first FDA-approved drug specifically for MASH. It works by targeting thyroid hormone receptors in the liver to reduce fat and inflammation. It is particularly effective for patients with advanced fibrosis, but note that about 70% of patients may not respond. It is a valuable option for those who do not respond to GLP-1RAs or SGLT2-is, or who need liver-specific treatment.

Incretin therapies are associated with gastrointestinal side effects and potential risks of gallstone disease and pancreatitis, requiring careful patient selection and monitoring, particularly in those with a history of these conditions.

While incretin therapies are effective for MASH, patients should be aware of common side effects like nausea and potential risks like gallstones or pancreatitis. These risks can be managed with slow dose titration, dietary adjustments, and regular monitoring, making the therapy safe for most patients when used appropriately.

Higher plasma levels of the specific nephronectin (NPNT) splice isoform, driven by increased body fat mass, causally increase the risk of severe COVID-19 and hospitalization.

If you have higher body fat mass, your body produces more of a specific protein called NPNT (specifically a splice isoform), which increases your risk of severe COVID-19. Reducing body fat mass and increasing fat-free mass through diet and exercise can lower these NPNT levels, thereby reducing your risk of severe outcomes from COVID-19.

Lower adipose NPR-C mRNA expression and higher NPR-A mRNA expression after weight loss predict better long-term weight maintenance and improved insulin sensitivity, independent of the weight maintenance intervention.

Your body's molecular response to weight loss (specifically the ANP system in fat tissue) may predict how well you maintain your weight and insulin sensitivity long-term. While you cannot change this directly, it suggests that personalized monitoring might be needed for those with less favorable molecular profiles.

Setmelanotide, an MC4R agonist, significantly reduces hunger and improves health-related quality of life in patients with POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome (BBS).

If you or your child has a confirmed diagnosis of POMC, LEPR, or BBS-related obesity, standard diet and exercise plans are unlikely to resolve the insatiable hunger (hyperphagia) because they don't fix the underlying genetic signaling error. Setmelanotide is an approved targeted therapy that directly addresses this mechanism, significantly reducing hunger scores and improving quality of life in clinical trials. Consult a specialist in rare metabolic disorders to determine eligibility.

Leptin replacement therapy is effective for reducing hunger and weight in patients with congenital leptin deficiency (homozygous LEP variants) but is ineffective in patients with defects downstream of the leptin receptor (e.g., POMC, PC1/3, MC4R deficiencies).

Leptin injections are highly effective for the rare condition of congenital leptin deficiency, significantly reducing hunger and weight. However, they are useless for patients with other genetic causes of obesity (like POMC or MC4R defects) because the body's ability to respond to leptin is broken downstream. Genetic testing is essential before considering this therapy.

Activation of the Area Postrema (AP) by GLP-1R agonists induces aversion (nausea) but is not necessary for appetite suppression, which is mediated by other brainstem regions like the Nucleus Tractus Solitarius (NTS).

Current GLP-1 drugs cause nausea by activating the Area Postrema in the brain, but weight loss is achieved by activating other brainstem areas (NTS). This separation suggests future drugs could be designed to minimize nausea while maintaining weight loss benefits.

Bariatric surgery (RYGB, VSG) and GLP-1R agonists share common neural targets in the brainstem (NTS, lPBN, CeA) and hypothalamus, suggesting overlapping mechanisms of action despite different peripheral origins.

Bariatric surgery and GLP-1 medications both work by activating specific brain pathways that reduce hunger and food intake. This shared mechanism explains why both are effective for severe obesity, even though one is surgical and the other is pharmacological.

Inhibiting Gs signaling specifically in K cells reduces plasma GIP levels and worsens glucose tolerance after refeeding.

This finding highlights that the natural Gs-mediated signaling in gut K cells is essential for maintaining normal blood sugar levels after eating. Disrupting this specific pathway impairs the body's ability to manage glucose spikes.

Elevated plasma levels of COL6A3-derived endotrophin, driven by increased body mass index (BMI), causally mediate an increased risk of coronary artery disease (CAD).

This research highlights that high body fat increases a specific protein fragment called endotrophin, which directly contributes to heart disease risk. The good news is that reducing body fat lowers these levels, suggesting that weight management strategies are effective not just for general health, but specifically for mitigating this biological pathway to heart disease.

Diet-induced changes in endogenous gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) do not reliably predict or control ad libitum energy intake in humans.

Do not rely on macronutrient manipulation (like Keto or Low-Fat) to regulate your appetite through hormones. This study proves that even when hormones change significantly, they do not predict how much you will eat. Instead, focus on food properties: lower energy density and fewer hyper-palatable combinations (fat/sugar/sodium) are more effective for controlling intake than hormone-targeting diets.

Endogenous gut hormone concentrations achieved through dietary changes are orders of magnitude lower than pharmacological doses, explaining why diet fails to suppress appetite while drugs succeed.

You cannot replicate the effects of GLP-1 drugs (like Ozempic) through diet alone because the hormonal concentrations achieved by eating are too low. Diet changes affect hormones, but not enough to significantly reduce appetite or energy intake.

Genetic loss-of-function variants of the GIP receptor are associated with lower body mass index (BMI) and reduced obesity prevalence in humans.

People with certain genetic variations that reduce GIP receptor function tend to have lower body weight. This genetic insight supports the development of drugs that block GIP receptors to achieve similar weight loss benefits.

Semaglutide increases the risk of non-serious gastrointestinal adverse events, specifically nausea, vomiting, and diarrhea, in patients at increased risk of cardiovascular events.

Expect stomach issues like nausea, vomiting, or diarrhea when starting semaglutide. These are common, usually get better over time, and are not considered 'serious' adverse events. Managing diet and starting with a low dose can help mitigate these effects.

High-dose tirzepatide (15mg/week) is associated with a significantly increased risk of overall gynecologic tumors compared to controls, with an odds ratio of 2.37.

If you are taking high-dose tirzepatide (15mg/week), be aware that this network meta-analysis found a statistically significant increase in gynecologic tumor risk compared to controls. The absolute risk increase is small (0.57%), but it exists. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Both high-dose (15mg/week) and low-dose (5mg/week) tirzepatide are associated with a significantly elevated risk of intra-uterus tumors.

If you are taking tirzepatide (whether 5mg or 15mg weekly), be aware that this network meta-analysis found a statistically significant increase in the risk of intra-uterus tumors. The risk appears to be present at both low and high doses. Discuss this with your doctor to weigh the metabolic benefits against this potential risk, especially if you have other predisposing factors for gynecologic cancers.

Tirzepatide reduces the incidence of heart failure hospitalizations, need for treatment intensification, and mortality due to cardiovascular causes in patients with heart failure and reduced ejection fraction.

If you have heart failure and reduced ejection fraction, Tirzepatide can reduce your risk of hospitalization and cardiovascular mortality.

Initiation of GLP-1 receptor agonists (GLP-1RA) in older adults with type 2 diabetes on stable levothyroxine therapy significantly increases the risk of new-onset atrial fibrillation or flutter (AF/Aflutter) compared to SGLT2 inhibitors.

If you take levothyroxine and start a GLP-1RA (like Ozempic or Wegovy), your thyroid hormone levels may become too high because you lose weight or absorb the medication differently. This increases your risk of irregular heartbeats (AF). You need closer monitoring of your TSH levels and likely a reduction in your levothyroxine dose shortly after starting the GLP-1RA to prevent this.

GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide) reduce hepatic lipid accumulation in MASLD patients, primarily through indirect mechanisms involving weight loss and reduced fatty acid deposition, and directly by improving insulin sensitivity and suppressing de novo lipogenesis.

GLP-1 agonists like semaglutide and tirzepatide are effective treatments for reducing liver fat in people with MASLD, especially if they also have type 2 diabetes or obesity. They work by improving insulin sensitivity and directly reducing fat production in the liver, in addition to helping with weight loss. While they significantly reduce liver fat, they may not reverse advanced scarring (fibrosis). Consistency is key, as side effects and cost can lead to stopping treatment.

GLP-1 receptor agonists have limited efficacy in reversing advanced hepatic fibrosis compared to their ability to reduce hepatic steatosis.

If you have advanced liver scarring (fibrosis), GLP-1 medications may not reverse it, even though they will likely reduce liver fat. Newer multi-agonists (like resmetirom or dual agonists) might be needed for fibrosis.

Retatrutide increases the incidence of adverse events, particularly nausea, vomiting, and decreased appetite, in a dose-dependent manner compared to placebo.

While effective, retatrutide causes more side effects than placebo, including nausea, vomiting, and constipation. These side effects increase with higher doses (8mg and 12mg). Patients should be prepared for these potential issues, which may affect adherence.

Genetic factors significantly predispose individuals to obesity, with heritability estimates exceeding 70% for fat difference, involving genes like LEP, LEPR, and MC4R.

If you have a family history of obesity, be aware that your body may fight weight loss more strongly. Focus on consistent, sustainable habits rather than quick fixes, and consider seeking professional guidance to navigate biological challenges.